Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Arghya Ray, PhD, Yan Song, PhD, Ting DU, PhD, Clifton C. Mo, MD, Arturo Olguin, Janice Chen, PhD, Christopher Brooks, PhD, Tariq I. Mughal, MD FRCP, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141571

Published: 2020

Journal Articles

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Haris Ali, MD, Abdulraheem Yacoub, MD, Eunice S. Wang, MD, Sangmin Lee, MD, Gary J. Schiller, MD, Christopher Brooks, PhD, Nicole Rupprecht, MS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Moshe Talpaz, MD, Minakshi S. Taparia, MBBS, Tariq I. Mughal, MD FRCP, Srdan Verstovsek, MD PhD, Joseph D. Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137572

Published: 2020

Journal Articles

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Aishwarya Krishnan, Maria Pagane, Mikhail Roshal, MD PhD, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 2967.

https://doi.org/10.1182/blood-2019-129397

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, Thomas G. Martin, III, MD, Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD, Claudia E. Paba-Prada, MD

Blood (2019) 134 (Supplement_1): 3145.

https://doi.org/10.1182/blood-2019-130410

Published: 2019

Journal Articles

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2018) 132 (Supplement 1): 765.

https://doi.org/10.1182/blood-2018-99-118966

Published: 2018

Journal Articles

Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML)

Aishwarya Krishnan, Bing Li, MD, Maria Pagane, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2018) 132 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2018-99-120035

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Gary J. Schiller, MD, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Arturo Olguin, Christopher Brooks, PhD, Vanessa Dunn, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2018) 132 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2018-99-119201

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

Mrinal M. Patnaik, MD MBBS, Haris Ali, MD, Vikas Gupta, MD FRCP, FRCPath, Gary J. Schiller, MD, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Arturo Olguin, Christopher Brooks, PhD, Vanessa Dunn, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2018) 132 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2018-99-119302

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Blood (2017) 130 (Supplement 1): 2583.

https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Mrinal M. Patnaik, MDMBBS, Vikas Gupta, MD PhD, Gary J. Schiller, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Animesh Pardanani, MBBS PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2017) 130 (Supplement 1): 2908.

https://doi.org/10.1182/blood.V130.Suppl_1.2908.2908

Published: 2017

Journal Articles

Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine

Jason Stephansky, Katsuhiro Togami, MDPhD, Mahmoud Ghandi, PhD, Joan Montero, PhD, Nick vonEgypt, Ross Lindsay, PhD, Christopher Brooks, PhD, Jon C. Aster, MD PhD, Cory Johannessen, PhD, Andrew A. Lane, MD PhD

Blood (2017) 130 (Supplement 1): 797.

https://doi.org/10.1182/blood.V130.Suppl_1.797.797

Published: 2017

Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2017) 130 (Supplement 1): 1298.

https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298

Published: 2017

Journal Articles

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Janice Chen, PhD, Vince Macri, MA, Pedro Herrera, MA, Christopher Brooks, PhD, Eric Rowinsky, MD

Blood (2014) 124 (21): 4500.

https://doi.org/10.1182/blood.V124.21.4500.4500

Published: 2014

Journal Articles

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

Arghya Ray, PhD, Deepika Sharma Das, PhD, Durgadevi Ravillah, PhD, Yan Song, PhD, Vincent Macri, Christopher Brooks, PhD, Eric Rowinsky, MD, Paul G. Richardson, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2014) 124 (21): 3441.

https://doi.org/10.1182/blood.V124.21.3441.3441

Published: 2014

Journal Articles

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

Lina Han, PhD, Eric Rowinsky, MD, Christopher Brooks, PhD, Tomasz Zal, M. Anna Zal, Jared K Burks, PhD, Jin Zhou, MD PhD, Stefan O. Ciurea, MD, Gheath Alatrash, Jorge E. Cortes, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Farhad Ravandi, MD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 981.

https://doi.org/10.1182/blood.V124.21.981.981

Published: 2014

Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia

Christopher Brooks, PhD, Janice Chen, PhD, David M. Lucas, PhD, Natarajan Muthusamy, DVM, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2014) 124 (21): 5663.

https://doi.org/10.1182/blood.V124.21.5663.5663

Published: 2014

Journal Articles

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms

Terra Lasho, PhD, Christy Finke, BS, Teresa K. Kimlinger, Darci Zblewski, CNP, Dong Chen, MD PhD, Mrinal M. Patnaik, MBBS, Curtis A. Hanson, MD, Christopher Brooks, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 5577.

https://doi.org/10.1182/blood.V124.21.5577.5577

Published: 2014

Journal Articles

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Christopher Brooks, PhD, Vincent Macri, Arnaldo Albini, MD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 4104.

https://doi.org/10.1182/blood.V122.21.4104.4104

Published: 2013

Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 2682.

https://doi.org/10.1182/blood.V122.21.2682.2682

Published: 2013

NARROW

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML)

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only